A novel GSH depletor for simultaneous ferroptosis and cuproptosis Activation in hepatocellular carcinoma
Biochemical Pharmacology · 2026-01 · 243 · 117488
DOI: 10.1016/j.bcp.2025.117488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-01. Verfasst von Haoyu Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China. Hauptthemen laut MEDLINE: Ferroptosis, Carcinoma, Hepatocellular, Liver Neoplasms, Glutathione. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province, Natural Science Foundation of Hunan Province, Hunan University of Chinese Medicine.
Abstract (Originalsprache)
Ferroptosis and cuproptosis are two important new forms of ion-dependent cell death, whose processes can be inhibited by high levels of glutathione (GSH) within cells. Therefore, reducing GSH levels is a key strategy for inducing ferroptosis and cuproptosis. Herein, we successfully developed a curcumin (Cur) derivative, bisdemethylcurcumin (bm-Cur), as a novel GSH depletor that simultaneously induces ferroptosis and cuproptosis in hepatocellular carcinoma (HCC). The unique polyphenolic hydroxy structure and double α, β-unsaturated ketone structure of bm-Cur confers its potent GSH scavenging ability, which can effectively deplete GSH by simultaneously inhibiting GSH synthesis and directly consuming GSH levels, ultimately inducing ferroptosis and cuproptosis. Notably, bm-Cur can target mitochondria, induce mitochondrial lipid peroxidation and mitochondrial damage, thereby promoting ferroptosis and cuproptosis-mediated cell death, which demonstrates potential for anti-HCC activity in vitro and in vivo. Moreover, bm-Cur exhibited very low cytotoxicity, excellent biosafety and biocompatibility. In conclusion, this study suggests that bm-Cur may be a novel ferroptosis and cuproptosis activator with significant development potential for further application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
- School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China; Hunan Engineering and Technology Research Center for Health Products and Life Science, Hunan University of Chinese Medicine, Changsha 410…
- Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China.
- School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China. Electronic address: 003994@hnucm.edu.cn.
Förderung
- Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province
- Natural Science Foundation of Hunan Province
- Hunan University of Chinese Medicine
- National Natural Science Foundation of China
Zitieren
APA
Yang, H., Chen, X., Huang, S., Dai, H., Xiao, Z., Fan, J., Zhang, H., Du, K., & Qin, Y. (2026). A novel GSH depletor for simultaneous ferroptosis and cuproptosis Activation in hepatocellular carcinoma. Biochemical Pharmacology, 243, 117488. https://doi.org/10.1016/j.bcp.2025.117488
Vancouver
Yang H, Chen X, Huang S, Dai H, Xiao Z, Fan J, et al. A novel GSH depletor for simultaneous ferroptosis and cuproptosis Activation in hepatocellular carcinoma. Biochemical Pharmacology. 2026;243:117488. doi:10.1016/j.bcp.2025.117488
BibTeX
@article{Yang2026,
author = {Yang, Haoyu and Chen, Xin and Huang, Siqi and Dai, Hongfang and Xiao, Zuowei and Fan, Jialong and Zhang, Honggang and Du, Ke and Qin, Yan},
title = {A novel GSH depletor for simultaneous ferroptosis and cuproptosis Activation in hepatocellular carcinoma},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {243},
pages = {117488},
doi = {10.1016/j.bcp.2025.117488}
}
EUVIMED